180
Participants
Start Date
December 12, 2020
Primary Completion Date
July 11, 2021
Study Completion Date
July 11, 2021
Nebulized Lidocaine
will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).
Nebulized dexmedetomidine
will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).
Nebulized lidocaine and dexmedetomidine
will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.
Placebo
will receive nebulized saline 0.9% (5 ml) as control group.
Ain Shams University, Cairo
Ain Shams University Hospitals, Cairo
Ain Shams University
OTHER